Heparanase Stimulation of Protease Expression Implicates It as a Master Regulator of the Aggressive Tumor Phenotype in Myeloma
Open Access
- 1 November 2008
- journal article
- Published by Elsevier BV
- Vol. 283 (47), 32628-32636
- https://doi.org/10.1074/jbc.m806266200
Abstract
No abstract availableKeywords
This publication has 67 references indexed in Scilit:
- Interactions of myeloma cells with osteoclasts promote tumour expansion and bone degradation through activation of a complex signalling network and upregulation of cathepsin K, matrix metalloproteinases (MMPs) and urokinase plasminogen activator (uPA)Experimental Cell Research, 2008
- The syndecan-1 heparan sulfate proteoglycan is a viable target for myeloma therapyBlood, 2007
- Osteoblasts promote migration and invasion of myeloma cells through upregulation of matrix metalloproteinases, urokinase plasminogen activator, hepatocyte growth factor and activation of p38 MAPKBritish Journal of Haematology, 2007
- Retracted: RNAi‐mediated downregulation of urokinase plasminogen activator receptor and matrix metalloprotease‐9 in human breast cancer cells results in decreased tumor invasion, angiogenesis and growthInternational Journal of Cancer, 2007
- Heparanase influences expression and shedding of syndecan-1, and its expression by the bone marrow environment is a bad prognostic factor in multiple myelomaBlood, 2007
- Heparanase deglycanation of syndecan-1 is required for binding of the epithelial-restricted prosecretory mitogen lacritinThe Journal of cell biology, 2006
- FGF2 Binding, Signaling, Angiogenesis Are Modulated by Heparanase in Metastatic Melanoma CellsNeoplasia, 2006
- Growth factor–induced shedding of syndecan-1 confers glypican-1 dependence on mitogenic responses of cancer cellsThe Journal of cell biology, 2005
- Heparanase Uptake Is Mediated by Cell Membrane Heparan Sulfate ProteoglycansPublished by Elsevier BV ,2004
- Mammalian heparanase: involvement in cancer metastasis, angiogenesis and normal developmentSeminars in Cancer Biology, 2002